Please login to the form below

Not currently logged in
Email:
Password:

lonafarnib

This page shows the latest lonafarnib news and features for those working in and with pharma, biotech and healthcare.

Deals in development

It doubled its phase III anticancer portfolio, with Novacea's high-dose capsule formulation of calcitriol, DN-101 (Asentar), joining its farnesyl protein transferase inhibitor lonafarnib (Sarasar) at the market end

Latest news

More from news
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest Intelligence

More from intelligence
Approximately 1 fully matching, plus 0 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
dna Communications

Healthcare communications with unique thinking, insight and attitude...

Latest intelligence

NHS regional footprints
What to expect from 2019...
Not another weight-loss ad
Christmas is over and the gyms are packed, it’s a never-ending tale. But why do we do it to ourselves every year?...
China’s clinical trial shake-up
As many of the obstacles to running clinical trials in China fall away, the country is proving to be a better research location...

Infographics